Filing Details
- Accession Number:
- 0000899243-17-021595
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-07 16:05:44
- Reporting Period:
- 2017-09-05
- Accepted Time:
- 2017-09-07 16:05:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1631650 | Aimmune Therapeutics Inc. | AIMT | Pharmaceutical Preparations (2834) | 452748244 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1664251 | E. Susan Barrowcliffe | Aimmune Therapeutics, Inc. 8000 Marina Boulevard, Suite 300 Brisbane CA 94005-1884 | General Manager, Europe | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 Par Value | Acquisiton | 2017-09-05 | 3,223 | $3.02 | 3,223 | No | 4 | M | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2017-09-05 | 3,223 | $22.00 | 0 | No | 4 | S | Direct | |
| Common Stock, $0.0001 Par Value | Acquisiton | 2017-09-06 | 15,167 | $3.02 | 15,167 | No | 4 | M | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2017-09-06 | 15,167 | $22.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option(right to buy) | Disposition | 2017-09-05 | 3,223 | $0.00 | 3,223 | $3.02 |
| Common Stock | Stock Option(right to buy) | Disposition | 2017-09-06 | 15,167 | $0.00 | 15,167 | $3.02 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 203,567 | 2025-05-13 | No | 4 | M | Direct | |
| 188,400 | 2025-05-13 | No | 4 | M | Direct |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- The transaction was executed in multiple trades in prices ranging from $22.00 to $22.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The option is immediately exercisable in full or in part. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from May 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Billionaire Hedge Funds
